Quarterly ResultAug 6, 2026, 10:16 AM
Whitehawk Therapeutics Q2 Net Loss $16.6M; Cash Runway into 2H 2028
AI Summary
Whitehawk Therapeutics reported a net loss of $16.6 million for the second quarter of 2026, a substantial improvement from a $52.6 million net loss in the prior year quarter. The company's cash, cash equivalents, and short-term investments stood at $190.0 million as of June 30, 2026, which is expected to fund operations into the second half of 2028, partly due to an $87.5 million private placement equity financing. Whitehawk also highlighted continued progress in its clinical pipeline, with ongoing enrollment in Phase 1 trials for HWK-007 and HWK-016, and the planned initiation of a Phase 1 trial for HWK-206 in Q3 2026, alongside new strategic partnerships.
Key Highlights
- Net loss for Q2 2026 was $16.6 million, a significant reduction from $52.6 million in Q2 2025.
- Cash, cash equivalents and short-term investments totaled $190.0 million as of June 30, 2026.
- Cash balance is anticipated to fund operations into the second half of 2028.
- Secured an $87.5 million private placement equity financing in May 2026.
- Research and development expenses decreased to $12.9 million in Q2 2026 from $48.8 million in Q2 2025.
- Continued enrollment in Phase 1 trials for HWK-007 and HWK-016.
- Phase 1 trial for HWK-206 is on track to initiate in Q3 2026.
- Entered option agreement with Hangzhou DAC for CPT113 for up to five additional ADC programs.
Price Impact
More from WHWK